Vivoryon Therapeutics NV
AEX:VVY
Vivoryon Therapeutics NV
AEX:VVY
Price:
1.285
EUR
2.8%
Market Cap:
€38m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Popular Picks
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Vivoryon Therapeutics NV
Net Income (Common)
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
Vivoryon Therapeutics NV
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vivoryon Therapeutics NV
AEX:VVY
|
Net Income (Common)
-€20.6m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-6%
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Net Income (Common)
-€1.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Net Income (Common)
€162.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Net Income (Common)
-€196.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Net Income (Common)
-€24.5m
|
CAGR 3-Years
24%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Formycon AG
XETRA:FYB
|
Net Income (Common)
-€64.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
No Stocks Found
Vivoryon Therapeutics NV
Glance View
The company is headquartered in Halle, Sachsen-Anhalt and currently employs 16 full-time employees. The company went IPO on 2014-10-27.
VVY
Intrinsic Value
Not Available
See Also
What is Vivoryon Therapeutics NV's Net Income (Common)?
Net Income (Common)
-20.6m
EUR
-20.6m
EUR
Based on the financial report for Dec 31, 2024, Vivoryon Therapeutics NV's Net Income (Common) amounts to -20.6m EUR.
What is Vivoryon Therapeutics NV's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-6%
-6%
Over the last year, the Net Income (Common) growth was 27%. The average annual Net Income (Common) growth rates for Vivoryon Therapeutics NV have been -18% over the past three years , -21% over the past five years , and -6% over the past ten years .
